A5059593161- Malaria Research and Control
- Drug-Induced Hepatotoxicity and Protection
- Cancer Immunotherapy and Biomarkers
- Research on Leishmaniasis Studies
- Immunotherapy and Immune Responses
- Mosquito-borne diseases and control
- Pharmacogenetics and Drug Metabolism
- Trypanosoma species research and implications
- Acute Ischemic Stroke Management
- COVID-19 Clinical Research Studies
- Cell Adhesion Molecules Research
- SARS-CoV-2 and COVID-19 Research
- Cerebrovascular and Carotid Artery Diseases
- Drug Transport and Resistance Mechanisms
- Computational Drug Discovery Methods
- Immunodeficiency and Autoimmune Disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- CAR-T cell therapy research
- Viral Infections and Outbreaks Research
- Pharmacological Effects and Toxicity Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Mycobacterium research and diagnosis
- Analytical Methods in Pharmaceuticals
- Folate and B Vitamins Research
- Global Maternal and Child Health
Bioscience Research
2024
Age UK
2022-2024
Opsona Therapeutics (Ireland)
2016-2018
Stevenage Bioscience Catalyst
2012-2014
Aptiv (United Kingdom)
2012-2014
Aptiv (Ireland)
2011
Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide single-dose oral cure in humans. has successfully completed Phase I clinical trials, where it was shown be safe at doses up 1,600 mg and currently undergoing IIa trials malaria patients. Herein, we describe the discovery of exceptional pharmacokinetic properties that led its selection as development candidate. In vitro, fast-acting against all asexual erythrocytic Plasmodium falciparum stages with IC 50...
Pyronaridine was synthesized in 1970 at the Institute of Chinese Parasitic Disease and has been used China for over 30 years treatment malaria. high potency against Plasmodium falciparum, including chloroquine-resistant strains. Studies various animal models have shown pyronaridine to be effective strains resistant other anti-malarials, chloroquine. Resistance appears emerge slowly is further retarded when combination with particular, artesunate. toxicity generally less than that...
To assess the safety and pharmacokinetics of a new synthetic ozonide antimalarial, OZ439, in first-in-man, double-blind study healthy volunteers.OZ439 was administered as single oral daily doses capsule formulation (50-1200 mg) or an dispersion (400-1600 mg, fed fasted states) for up to 3 days (200-800 mg day(-1)). Plasma concentrations OZ439 its metabolites were measured by LC-MS.The pharmacokinetic (PK) profile characterized t(max) around h, followed multiphasic with terminal half-life...
Pyronaridine-artesunate (PA) is indicated for the treatment of acute uncomplicated Plasmodium falciparum and vivax malaria. Individual patient data on safety outcomes were integrated from six randomized clinical trials conducted in Africa Asia patients with microscopically confirmed P. (five studies) or (one study) Efficacy against was evaluated across three Phase III trials. The population included 2,815 to PA, 1,254 comparators: mefloquine + artesunate (MQ AS), artemether-lumefantrine...
FMPV-1 is a component of FMPV-3, an investigational cancer-specific vaccine and being developed to activate anti-cancer T cell responses targeting frameshift mutations MSI-H cancers. designed against transforming growth factor β receptor 2 (TGFβR2) mutation. Microsatellite instability high (MSI-H) gastrointestinal cancers frequently harbour TGFβR2 mutations. This first-in-human, phase 1, single centre, open-label study included 16 healthy male subjects who received (0.15 mg/injection) plus...
Background In Phase II/III randomized controlled clinical trials for the treatment of acute uncomplicated malaria, pyronaridine–artesunate demonstrated high efficacy and a safety profile consistent with that comparators, except asymptomatic, mainly mild-to-moderate transient increases in liver aminotransferases were reported some patients. Hepatic safety, tolerability, effectiveness have not been previously assessed under real-world conditions Africa. Methods findings This single-arm,...
This exploratory study investigated four repurposed anti-infective drug regimens in outpatients with COVID-19.This phase 2, single centre, randomised, open-label, clinical trial was conducted South Africa between 3rd September 2020 and 23rd August 2021. Symptomatic aged 18-65 years, RT-PCR confirmed SARS-CoV-2 infection were computer randomised (1:1:1:1:1) to standard-of-care (SOC) paracetamol, or SOC plus artesunate-amodiaquine (ASAQ), pyronaridine-artesunate (PA), favipiravir nitazoxanide...
BackgroundHigh-quality evidence for the therapeutic efficacy and effectiveness of antimalarials infections caused by Plasmodium malariae, ovale spp, mixed-Plasmodium is scarce. In this study, we aimed to analyse pyronaridine–artesunate treatment non-falciparum mixed-species from a large phase 3b/4 clinical trial in central Africa.MethodsThis post-hoc analysis was done random subset samples two sites (in Democratic Republic Congo Gabon) CANTAM-Pyramax assessing pyronaridine-artesunate...
ABSTRACT The objectives of this study were to characterize any drug-drug interaction between the antimalarial Pyramax (pyronaridine-artesunate [PA]) and CYP2D6 probe substrate metoprolol assess safety 60-day or 90-day PA redosing, particularly with regard liver biochemistry parameters. Healthy adult subjects randomized arm A ( n = 26) B 30), administered 100 mg tartrate in first period, third three daily doses second alone redosing period. received three-day regimen after 60 days...
TPS3145 Background: Response to existing chemotherapeutics (chemo) can be limited by exposure, itself systemic toxicity. Interstitial fluid pressure impede transport of drugs with, in some cases, <5% chemo penetrating the target tumour. ACT is an innovative platform technology using sonopermeation induce ultrasound (US) mediated targeting therapeutic agent choice co-administration emulsion microbubble-microdroplet clusters (PS101) for intravenous injection. Dual-frequency US applied tumor...
Abstract Background Children are particularly at risk of malaria. This analysis consolidates the clinical data for pyronaridine–artesunate (PA) paediatric granules in children from three randomized trials and a real-world study (CANTAM). Methods An integrated safety individual patient included patients with microscopically-confirmed Plasmodium falciparum , body weight ≥ 5 kg to < 20 kg, who received least one dose drug (paediatric population). PA was administered once daily 3 days; two...
<title>Abstract</title> FMPV-1 is a component of FMPV-3, an investigational cancer-specific vaccine and being developed to activate anti-cancer T-cell responses targeting frameshift mutations MSI-H cancers. designed against transforming growth factor β receptor 2 (TGFβR2) mutation. Microsatellite instability High (MSI-H) gastrointestinal cancers frequently harbour TGFβR2 mutations. This first-in-human, Phase 1, single centre, open-label study included 16 healthy male subjects who received...
<title>Abstract</title> FMPV-1 is a component of FMPV-3, an investigational cancer-specific vaccine and being developed to activate anti-cancer T-cell responses targeting frameshift mutations MSI-H cancers. designed against transforming growth factor β receptor 2 (TGFβR2) mutation. Microsatellite instability High (MSI-H) gastrointestinal cancers frequently harbour TGFβR2 mutations. This first-in-human, Phase 1, single centre, open-label study included 16 healthy male subjects who received...
Pyronaridine-artesunate (PA) is a registered artemisinin-based combination therapy, potentially useful for mass drug administration campaigns. However, further data are needed to evaluate its efficacy, safety and tolerability as full or incomplete treatment in asymptomatic Plasmodium falciparum-infected individuals.This phase II, multi-center, open label, randomized clinical trial was conducted The Gambia Zambia. Participants with microscopically confirmed P. falciparum infection were...
Global health, particularly in underserved settings can benefit immensely from well-trained community health workers (CHWs) supporting primary healthcare interventions. They reduce morbidity and mortality of infectious diseases like malaria. Disease control programs a tight link between CHWs communities several studies have shown the participation non-facility-based malaria program activities for reducing malaria-related children. Because are often part trusted by served communities, they...